Table 4 All of the patients’ clinical characteristics and features grouped by the change of mRS
mRS change (ΔmRS) = mRS (pre) – mRS (post) | P value | ||
|---|---|---|---|
Parameter | No respond or worse (ΔmRS ≤ 0) (-1,0) | Improvement (ΔmRS ≥ 1) (1,2) | |
N | 11 | 15 | |
Age | 41.82 ± 19.894 | 41.2 ± 19.633 | 0.938 |
Gender (female:male) | 4:7 | 5:10 | 0.873 |
AE Antibody (n) | NMDAR: 6 | NMDAR: 10 | |
GABA-BR: 4 | GABA-BR: 1 | ||
LGI1: 1 | LGI1: 2 | ||
AMPAR: 2 | |||
Neoplasm (n%) | 45.5% | 26.7% | 0.32 |
Serum antibody positive | 9 | 12 | 0.557 |
CSF antibody positive | 11 | 13 | 0.557 |
the duration of the disease until the time of DFPP (days) (range) | 34 (8–243) | 75.5 (21–235) | 0.183 |
Plasma exchange volume of DFPP (ml/kg) (range) | 46 (33–64) | 48 (41–76) | 0.317 |
DFPP circles (IQR) | 3 (3,4) | 4 (3,5) | 0.253 |